INS and fatty liver disease: EPM301 not only modulated energy utilization, but also restored glucose and insulin homeostasis as well as reduced obesity-induced hepatic steatosis and liver injury, and normalized hyperlipidemia, an effect that is most likely modulated via affecting cellular hepatic LDL metabolism.